Summary SARS-CoV-2 variants that attenuate antibody neutralization could jeopardize vaccine efficacy. We recently reported the protective activity of an intranasally administered spike protein-based chimpanzee adenovirus-vectored vaccine (ChAd-SARS-CoV-2-S) in animals, which has advanced to human trials. Here, we assessed its durability, dose response, and cross-protective activity in mice. A single intranasal dose of ChAd-SARS-CoV-2-S induced durably high neutralizing and Fc effector antibody responses in serum and S-specific IgG and IgA secreting long-lived plasma cells in the bone marrow. Protection against a historical SARS-CoV-2 strain was observed across a 100-fold vaccine dose range and over a 200-day period. At 6 weeks or 9 months after vaccination, serum antibodies neutralized SARS-CoV-2 strains with B.1.351, B.1.1.28, and B.1.617.1 spike proteins and conferred almost complete protection in the upper and lower respiratory tracts after challenge with variant viruses. Thus, in mice, intranasal immunization with ChAd-SARS-CoV-2-S provides durable protection against historical and emerging SARS-CoV-2 strains. Graphical abstract Highlights • Immunization with ChAd-SARS-CoV-2 S induces durable immunity • Intranasal ChAd-SARS-CoV-2 S induces inhibitory IgG and IgA Abs • Abs induced by intranasal ChAd-SARS-CoV-2 S have robust Fc effector functions • Intranasal ChAd-SARS-CoV-2 S confers cross-protection against variants of concern Hassan et al. show that immunization with ChAd-SARS-CoV-2-S is durably immunogenic and protects against SARS-CoV-2 challenge in a dose-dependent manner. Many months after single-dose intranasal immunization, ChAd-SARS-CoV-2 confers protection against variants of concerns of SARS-CoV-2 in both the upper and lower respiratory tracts of mice.
【저자키워드】 COVID-19, SARS-CoV-2, Vaccine, Pathogenesis, antibody, variants of concern, mice, mucosal immunity, Durability, 【초록키워드】 viruses, IgG, Efficacy, vaccination, cross-protection, Immunity, B.1.351, protection, Antibody Response, variant, SARS-CoV-2 variant, immunization, Spike protein, Bone marrow, vaccine dose, serum, IgA, B.1.617.1, B.1.1.28, Neutralizing, serum antibody, trials, intranasal, function, Antibody neutralization, Protective, dose, Lower respiratory tract, Abstract, dose-dependent manner, dose response, immunogenic, SARS-CoV-2 strains, SARS-CoV-2 strain, inhibitory, Administered, Complete, neutralized, robust, PROTECT, intranasally, reported, provide, induce, cross-protective, secreting, attenuate, chimpanzee adenovirus-vectored vaccine, long-lived plasma cell, 【제목키워드】 SARS-CoV-2 variant, intranasal, PROTECT,